Découvrez les Meilleures Cliniques et Coûts pour Votre Thérapie de privation androgénique en République de Corée en 2026

Standard androgen-deprivation therapy in South Korea primarily utilizes medical castration via LHRH agonists or antagonists to suppress testosterone. Combined androgen blockade is highly prevalent, with approximately 60.8% to 78% of patients receiving this dual-action treatment to prevent testosterone flares and improve long-term outcomes.

• Medical castration: Preferred over surgery using leuprolide, goserelin, or triptorelin injections.
• Surgical castration: Bilateral orchiectomy is less common, occurring in only 8.5% of cases.
• CAB adoption: Usage rates reach 91.7% in specific primary androgen-deprivation therapy cohorts.
• Treatment intensifiers: Guidelines recommend adding abiraterone or docetaxel for metastatic prostate cancer.

Bookimed Expert Insight: While Western protocols often favor monotherapy, South Korean oncology centers like Samsung Medical Center and Severance Hospital prioritize combined androgen blockade. Our data suggests this preference stems from national insurance coverage, making comprehensive dual-therapy more accessible in Korea than in the US, where hormone therapy averages $12,500.

Patient Consensus: Patients often find that Korean doctors default to combined therapy even for lower-risk cases. Many suggest preparing for more intense initial side effects like hot flashes when following these aggressive dual-action protocols.

Androgen deprivation therapy (ADT) increases the risk of osteoporosis and bone fractures in Korean patients significantly. Data indicates a 1.38-times higher risk for osteoporosis and 1.8-times higher risk for fractures compared to non-ADT groups. This risk accumulates proportionally with treatment duration beyond one year.

• Cumulative risk: Osteoporosis hazard ratios rise from 1.29 to 1.64 after 3 years of treatment.
• Fracture incidence: Men receiving ADT are 1.8 times more likely to experience bone-related injuries.
• Prevalence rate: Approximately 67% of Korean prostate cancer patients on ADT develop low bone density.
• Early loss: Bone mineral density typically decreases most rapidly during the first year of therapy.

Bookimed Expert Insight: Korea's digital hospital leadership, including SNUBH with its BESTcare system, ensures high-precision monitoring of bone health indicators. This digital integration allows oncology centers to identify bone density decline earlier than manual systems. Patients at centers like Samsung Medical Center benefit from presidential-standard care protocols that prioritize early intervention.

Patient Consensus: Patients emphasize requesting a baseline DEXA scan before starting therapy to track decline. Many report that doctors now proactively warn about height loss or back pain as early fracture signs.

Docetaxel added to ADT for Korean men with metastatic hormone-sensitive prostate cancer is effectively comparable to Western standards. It demonstrates a median time to progression of 18.0 months. However, Korean patients face significantly higher risks of severe neutropenia, often requiring prophylactic G-CSF support.

• Oncologic effectiveness: Time to castration resistance is 18.0 months, exceeding the 14.9 months in CHAARTED cohorts.
• Survival outcomes: PSA response levels below 0.2 ng/mL reach 41–45%, surpassing the 27.7% Western average.
• Hematologic toxicity: Severe Grade 3 or 4 neutropenia affects 63.5% of Korean patients versus 12.1% Western.
• Clinical management: Many Korean oncologists utilize dose reductions to 60–75 mg/m² to maintain treatment safety.

Bookimed Expert Insight: Samsung Medical Center and Severance Hospital carry massive patient volumes, reaching millions annually. This immense data pool allows Korean oncologists to refine dosing strategies for local genetics. They frequently use ISO-standardized protocols to manage higher toxicity risks without compromising the 78% treatment completion rate.

Patient Consensus: Patients advocate for early intervention, often regretting treatment delays rather than manageable toxicity. Many suggest preparing for 6 cycles by stocking anti-nausea meds and closely monitoring blood counts.

Primary androgen deprivation therapy in South Korea shifted from a dominant standalone treatment to a targeted component of multimodal care. Use dropped from 82.9% to 75.3% as robot-assisted surgery and radiation became primary interventions for localized prostate cancer within JCI-accredited Seoul centers.

• Treatment shift: ADT monotherapy is now frequently replaced by robotic surgery or radiotherapy.
• Intensification standards: Metastatic cases now prioritize combining ADT with abiraterone, enzalutamide, or docetaxel.
• Surgical growth: Robot-assisted radical prostatectomy became the leading surgical modality for younger Korean patients.
• Risk stratification: Clinicians now follow NCCN guidelines to avoid primary ADT in low-risk cases.

Bookimed Expert Insight: The data shows a massive shift toward surgical centers like Severance Hospital and Samsung Medical Center. These facilities handle millions of outpatients and prioritize robot-assisted systems over simple hormone therapy. While ADT remains a foundation, the 1,400+ doctors at top Seoul hospitals now use it largely to supplement high-tech robotic interventions.

Patient Consensus: Patients now see more open discussions regarding metabolic and bone-loss side effects of hormone treatments. Many report moving toward combined therapy or radiation to ensure better long-term quality of life.

Androgen-deprivation therapy in Korean men demonstrates a neutral or potentially protective association regarding cardiovascular and cerebrovascular events. Large-scale nationwide studies involving over 130,000 patients indicate that therapy is not an independent risk factor for stroke or heart disease after adjusting for age and comorbidities.

• Risk factors: Primary drivers of events are age, diabetes, and pre-existing hypertension.
• Long-term effects: Use exceeding 2 years may correlate with reduced ischemic risk.
• Clinical findings: Multivariable analysis confirms no increased need for bypass or angioplasty.
• Metabolic monitoring: Focused screening is recommended as metabolic syndrome may develop eventually.

Bookimed Expert Insight: While clinical data from major centers like Samsung Medical Center or Severance Hospital show neutral cardiac risks, the scale of Korean oncology is a factor. These facilities treat up to 4,000,000 outpatients annually. This high volume allows for specialized cardio-oncology teams that manage side effects more effectively than smaller international centers.

Patient Consensus: Patients emphasize the importance of quarterly lipid monitoring and daily blood pressure checks. Many credit concurrent exercise and diet programs for maintaining heart health throughout the treatment period.

The median time to progression from metastatic hormone-sensitive prostate cancer to castration-resistant prostate cancer (mCRPC) for Korean patients using androgen deprivation therapy alone typically ranges from 15 to 20 months. Population-based data specifically shows a median time of 19.7 months for those receiving LHRH agonists.

• Standard monotherapy: Luteinizing hormone-releasing hormone agonists alone show a median progression time of 19.7 months.
• High-risk variables: Patients with visceral metastases may progress much faster, sometimes within 9.4 months.
• Gleason score impact: Scores of 8 or higher are significantly associated with shorter progression-free survival.
• Korean clinical data: Real-world studies of primary androgen deprivation therapy estimate a 19-month median progression.

Bookimed Expert Insight: Leading Korean centers like Samsung Medical Center and Severance Hospital utilize advanced AI and robotic technologies to manage high-risk cases. Data suggests that patients treated at these high-volume facilities often benefit from precise monitoring protocols. This intensive tracking may explain why some Korean cohorts reach a 20.5-month median despite high-risk factors.

Patient Consensus: Patients emphasize the importance of tracking PSA doubling times monthly to catch progression early. Many suggest requesting genomic testing to better predict individual timelines and discuss treatment intensification before reaching the resistance stage.

Long-term androgen deprivation therapy in Korean men significantly reduces the risk of primary open-angle glaucoma and normal-tension glaucoma. Conversely, androgen suppression frequently triggers meibomian gland dysfunction, leading to chronic dry-eye syndrome and ocular surface discomfort that requires specialized ophthalmic monitoring during cancer treatment.

• Glaucoma protection: Korean studies shows a 19% lower risk of developing primary open-angle glaucoma.
• Duration impact: Protective effects against glaucoma persist for both short-term and long-term therapy durations.
• Dry-eye risk: Androgen deficiency causes meibomian gland atrophy, disrupting the tear film's essential lipid layer.
• Clinical monitoring: Specialist centers like Severance Hospital provide integrated oncology and ophthalmology care for surface issues.

Bookimed Expert Insight: While ADT provides a surprising protective layer against glaucoma, the high volume of patients at centers like Samsung Medical Center—serving over 2,000,000 annually—highlights a critical infrastructure for managing side effects. Patients often overlook the vision-hormone link, but Korean protocols increasingly integrate baseline eye exams at multidisciplinary clinics to catch meibomian changes before permanent atrophy occurs.

Patient Consensus: Many men report gritty sensations or blurry vision starting 6 months into treatment, often requiring preservative-free tears. Early use of fish oil and tracking eye irritation with an ophthalmologist helps manage these androgen-related surface changes.